MorningSignal
Research Platform
2026-04-11 21:47
Prepared: April 6, 2026 — Evening Run | Analyst: Automated EarningsBrief System Coverage Universe: US-listed stocks >$2B market cap
April 6 is the formal opening bell of Q1 2026 earnings season, but the night belongs to macro, not micro. Zero major-cap ($2B+) companies reported AMC on April 6 — the 13 companies on today's calendar are universally small-cap. The dominant after-hours event is entirely regulatory: the Trump CMS finalized 2027 Medicare Advantage (MA) payment rates at +2.48%, a massive positive surprise vs. the near-flat +0.09% advance notice from January, sending the managed care sector up 8–13% after hours. UNH (+9.9%), HUM (+13%), and CVS (+7.8%) all surged sharply. The PM should size up managed care exposure into tomorrow's open — this is the most actionable call of the quarter. The real earnings season kicks off Wednesday with Delta Air Lines (DAL) BMO, the first major S&P 500 Q1 reporter; Thursday brings WD-40 (WDFC) AMC.
Status: 13 companies reported on April 6, 2026. None were US-listed stocks above $2 billion market cap.
April 6 was the quietest Monday to open an earnings season in recent memory. Q1 2026 earnings season officially begins this week, but the first major S&P 500 reporters don't arrive until April 8 (Delta Air Lines, CarMax). The 13 companies reporting today are universally micro- or small-cap names.
Key market-moving after-hours event (regulatory, not earnings):
At market close on April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published the final CY 2027 Medicare Advantage and Part D Rate Announcement, finalizing a +2.48% average rate increase for MA plans in plan year 2027. This translates to approximately +$13 billion in incremental payments to private MA insurers.
The timeline of events: - January 26, 2026: CMS released the Advance Notice proposing only +0.09% (~$700M) for 2027. This was catastrophic — UNH fell 20.7% over two days, HUM plummeted 22%, CVS fell 13.3%, Elevance fell ~5%. - April 6, 2026 (today): CMS finalized at +2.48% — a near-25x improvement over the proposal, adding $13B to the system.
The final rule represents a full Trump administration reversal on the aggressive rate-restriction posture signaled in January. The administration preserved the phase-in of chart-review exclusions from risk adjustment (a headwind), but the effective growth rate more than compensates.
| Company | Ticker | AH Move | Context |
|---|---|---|---|
| Humana | HUM | +13.0% | Pure MA play; most leverage to rate increase; stock had been down ~40% from 2025 highs |
| UnitedHealth Group | UNH | +9.9% | Diversified (MA + Optum); rate increase removes dominant overhang |
| CVS Health | CVS | +7.8% | Aetna MA segment benefits; PBM/pharmacy segment provides additional earnings stability |
| Elevance Health | ELV | Surging (magnitude TBD) | Complex: beneficiary of rate increase, BUT CMS froze new MA enrollment in March 2026 due to misconduct findings; company in different regulatory posture |
| Centene | CNC | +5–7% est. | Smaller MA exposure vs. Medicaid focus; less direct benefit |
A. Headline Assessment This is not a routine regulatory update. The January advance notice had repriced the entire managed care sector as a structural short — the 20%+ declines reflected market pricing in a multi-year MA rate headwind that would permanently compress MCO margins. The final rule today fully reverses that thesis. The +2.48% effective rate, combined with a phased (not immediate) implementation of chart-review restrictions, gives MCOs full operating flexibility for 2027.
B. Individual Name Assessment
UNH (BUY — High Conviction) - Best risk-adjusted long in the sector. Pre-crisis, UNH was trading ~$650+; the January shock took it to the $430–480 range. At +9.9% tonight it recovers a portion of that. - Optum (health services) provides ~$30B+ revenue insulation entirely independent of MA rate decisions. - Q1 2026 earnings expected ~April 21. Street will likely revise FY2026 estimates upward materially tomorrow. - One-sentence PM call: UNH's multi-business model and scale make it the highest-conviction way to own the MA rate reversal; buy into tomorrow's strength.
HUM (BUY — Medium-High Conviction) - Humana is the purest-play Medicare Advantage insurer (>80% of revenue from MA). The +$13B system-wide rate increase disproportionately benefits HUM given its MA concentration. - Key risk: HUM entered 2026 in turnaround mode after significant 2025 MLR (medical loss ratio) deterioration. The rate increase buys time, but if HUM's Q1 2026 MLR (due ~April 28) shows the underlying trend hasn't stabilized, the stock will give back gains. - One-sentence PM call: Best pure-beta trade to own the CMS reversal, but size with discipline — MLR print at Q1 earnings is the gates test.
CVS (BUY — Medium Conviction) - CVS's Aetna MA segment is ~25% of total revenues; rate increase is meaningful but not as transformative as for HUM. - Additional tailwind: CVS has been dealing with PBM/spread pricing regulatory scrutiny; healthcare reform risk has moderated under the current administration. - One-sentence PM call: CVS is the value play in managed care — least rate-sensitive but most diversified, with a 4%+ dividend yield as a cushion.
ELV (HOLD — Low Conviction relative to peers) - Elevance has a different risk profile: CMS halted new MA enrollment in Elevance plans in March 2026 due to alleged misconduct/billing irregularities. - The rate increase helps ELV's existing book, but the enrollment freeze prevents organic MA member growth while competitors gain share. - ELV had already underperformed peers post-January shock for idiosyncratic reasons. - One-sentence PM call: Don't chase ELV's AH bounce — the enrollment freeze creates regulatory uncertainty that makes it structurally inferior to UNH/HUM/CVS in this rate environment.
C. Key Risk to the Bull Case If Q1 2026 MCO earnings (April 21–April 28 for major reporters) reveal medical cost trends running HOT — i.e., MLRs above 90%+ — the market will question whether the rate increase merely covers rising costs rather than expanding margins. Watch DAL this Wednesday as a proxy for overall consumer health: robust travel demand = consumer still healthy = likely not a medical-cost spiral.
Status: No major-cap ($2B+) BMO reporters identified for April 6, 2026 morning.
The 13 companies on today's calendar appear to be uniformly small-cap. No transcripts from today's morning are flagged for catch-up analysis.
Context for recent reporters (released March 31 – April 2, 2026): The prior week closed out a handful of off-cycle fiscal reporters. These were covered in earlier briefs; key items for context:
McCormick (MKC) — Q1 FY2026 reported March 31 (BMO): Beat on EPS ($0.66 vs. $0.61E, +8.2%) and revenue ($1.87B vs. $1.79BE, +4.5%). Organic sales +16.7% YoY boosted by McCormick de Mexico consolidation. However, the simultaneous announcement of a Unilever Foods acquisition (creating a ~$20B combined flavors/foods entity) dominated the reaction, sending MKC down ~7.15% premarket. As of April 6 midday, MKC was trading at $49.68 (+1.7%), suggesting partial recovery but ongoing integration risk digestion. Market cap: ~$6B.
FactSet Research (FDS) — Q2 FY2026 reported March 31 (BMO): Beat on EPS ($4.46 vs. $4.41E) and revenue ($611M vs. $610.5ME). Organic revenue growth +6.8% YoY. Raised FY2026 guidance; stock +5.6% on the day. Market cap: ~$17B.
Lamb Weston (LW) — Q3 FY2026 reported April 1 (BMO): Revenue $1.57B beat $1.54B estimate. Adjusted EPS $0.72 beat $0.64E. Raised mid-point of FY2026 guidance. JPMorgan noted results "better than feared." Market cap: ~$6B.
Cal-Maine Foods (CALM) — Q3 FY2026 reported approximately April 1: EPS $1.06 beat $0.82E (+29.3%); Revenue $667M beat $642ME (+3.9%). Specialty egg sales reached 50.5% of total (vs. 24.4% prior year) — structural mix shift executing. Prepared Foods now 9.5% of sales (vs. 0.8% prior year) — new segment contribution accelerating. Massive YoY revenue decline (-53%) reflects normalization from the extraordinary egg price spike of FY2025, not fundamental deterioration.
Conagra Brands (CAG) — Q3 FY2026 reported April 1 (AMC): GAAP EPS $0.42 beat $0.40E; Adjusted EPS $0.39 MISSED $0.40E. Revenue $2.80B beat $2.76BE (+1.4%). Organic net sales +2.4%. Narrowed FY2026 guidance with adjusted EPS guided lower to ~$1.70. Key headwind: gross profit down 7.4% YoY as input cost inflation offset pricing gains.
1. Regulatory Risk is the New Earnings Catalyst April 6 underscores that in healthcare, regulatory announcements (CMS rate notices) can move stocks more violently than any earnings release. The managed care sector lost and regained billions of market cap over just two CMS events (January advance notice shock, today's final rule relief). PMs must track CMS announcement calendars as primary event risk, not just quarterly earnings dates.
2. Q1 2026 Earnings Season Opens With High Bar The consensus expects +13.2% S&P 500 EPS growth for Q1 2026 — the highest hurdle in several years. Delta Air Lines on Wednesday will set the tone for the consumer and industrial economy. Any revenue softness (fuel, demand elasticity) would be a market-wide signal.
3. Early Reporters Show Input Cost Pressure Conagra (gross profit -7.4%), Lamb Weston (adjusted EPS below GAAP peers on cost basis) — early food sector reporters are managing through commodity inflation. This will be a recurring Q1 2026 theme for Consumer Staples.
4. McCormick's Unilever Deal Creates a Transformational Acquirer The $20B combined entity (MKC + Unilever Foods) reshapes the global flavor/condiments market. Expect analyst upgrades/downgrades as integration risk assessment matures over the next 30–60 days. MKC is dead money near-term but a compelling strategic long on a 2-year horizon if integration synergies ($600M/year by Year 3) execute.
Greenbrier Companies (GBX) — Q2 FY2026 (quarter ended February 28, 2026) - Report: AMC April 7, conference call 2:00 PM PDT - Analyst consensus: EPS ~$0.82–$0.98 (wide range), Revenue ~$663–667M - Key themes: Railcar backlog, steel cost trends, tariff impacts on manufacturing inputs - Market cap: ~$1.3–1.5B (may be below $2B threshold — confirm before sizing position) - Note: GBX fiscal Q2 coincides with a period of elevated steel tariff uncertainty under the current administration
Delta Air Lines (DAL) — Q1 2026 (BMO, 6:30 AM ET) - Consensus EPS: ~$0.62–0.64 (up from $0.46 in Q1 2025, +39% YoY) - Consensus Revenue: ~$14.8B ($13.88B per some estimates; DAL internal guide raised to $15–15.3B range) - DAL self-raised Q1 revenue guidance to high-single-digit growth, implying revenue could hit $15B+ - Watch for: Domestic vs. international demand split; fuel cost commentary ($90+ crude as backdrop); corporate travel trends; 2026 full-year EPS guidance ($6.50–7.50 range) - Catalyst: First major airline Q1 report sets tone for UAL, AAL, LUV later in April - Setup: If DAL beats AND raises, airlines and travel sector should rip. If DAL disappoints on margin (fuel headwinds), the sector re-rates lower despite top-line strength
CarMax (KMX) — Q4 FY2026 (April 8 — confirm BMO or AMC) - Key themes: Used vehicle pricing environment, financing spread, EV inventory mix - Analysts project EPS ~$0.21 — below prior-year norms, reflecting affordability pressure
WD-40 Company (WDFC) — Q2 FY2026 (AMC, 2:00 PM PDT conference call) - Street consensus EPS: ~$1.42 - Key themes: International exposure (FX headwinds), specialty product pricing power - Market cap ~$2.5B; niche quality compounder — watch for maintenance of long-term margin expansion narrative
Sources consulted: Bloomberg, STAT News, CNBC, Investing.com, GuruFocus, Quiver Quantitative, StockTitan, McCormick IR, FactSet IR, Benzinga, 24/7 Wall Street, The Motley Fool (Stock Market Today April 6)
Next scheduled run: EarningsBrief_2026-04-07_AM.md — Pre-open. Key item: Greenbrier (GBX) AMC results expected. Dominant focus: DAL Q1 2026 preview and sector setup ahead of Wednesday.